General Information

AdAlta Limited
1AD
http://www.adalta.com.au
Biotechnology
21
77

Current Price Data+

Current Price $0.270
Open $0.275
High $0.275
Low $0.270
Last Close $0.280
Volume 5912
Price Movement $0.01 ( 3.57% )
  • +Security prices are delayed by at least 20 minutes and are indicative only.

Stock Price

Company Overview

Business Description

AdAlta Limited (1AD) is a drug discovery and development company. 1AD is developing a novel technology platform that produces unique compounds known as i-bodies, that mimic the shape of shark antibodies and engineers their key stability features into human proteins, for therapeutic intervention in disease.

Financial Summary

Year to Feb NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2016 A 0.0 0.0 0.0% 0.0 0.0 0.0% 0.0%

Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
A F 2016 F A F 2016 F A F 2016 F
AdAlta (1AD) $22M 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
CSL (CSL) $63,991M -0.1719 0.2398 0.3433 45.4707 36.6758 27.3023 1.20% 1.25% 1.73%
Mesoblast (MSB) $864M 0.0000 0.0000 0.0000 9.3649 0.0000 0.0000 0.00% 0.00% 0.00%
Monash IVF Group (MVF) $404M 0.1852 0.1031 0.0742 14.0344 12.7226 11.8439 4.96% 5.50% 5.91%
Sirtex Medical (SRX) $757M 0.3228 -0.0659 0.1376 14.2299 15.2346 13.3919 2.29% 2.26% 2.33%

Financial Summary

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 1.94 0.00
Market 1.16 15.50 1.24 1.04
Sector 0.71 13.30 3.00 1.38

Directors

Name Position Start Date
Ms Samantha (Sam) Cobb Chief Executive Officer, Managing Director 29 Jun 2007
Dr Paul MacLeman Non-Executive Chairman, Non-Executive Director 16 Apr 2015
Ms Elizabeth (Liddy) McCall Non-Executive Director 16 Oct 2010
Dr John Chiplin Non-Executive Director 16 May 2014
Dr James Williams Non-Executive Director 16 Oct 2010
Dr Robert Peach Non-Executive Director 14 Nov 2016

Management

Name Position
Cameron Jones Chief Financial Officer,Company Secretary

Calendar of Events

Date Event
13 February 2018 Report (Interim)
18 September 2017 Report (Annual)
30 August 2017 Report (Prelim)

© 2017 Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only. DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.